论文部分内容阅读
目的探讨舒利迭治疗慢性阻塞性肺病稳定期的临床疗效。方法选择我院2007年2月～2009年2月慢性阻塞性肺病患者112例,均为稳定期患者。随机将上述患者分为对照组和治疗组。对照组54例在常规治疗基础上雾化吸入布地奈德0.3mg,2次/d。治疗组58例在常规治疗基础上吸入舒利迭(沙美特罗50μg和丙酸氟替卡松250μg)吸入,12h吸入1次,2次/d。两组治疗共8W。在治疗前和疗程结束后检测两组患者肺功能,并对其临床症状进行评分。结果疗程结束后,①临床症状评分:各组治疗后与治疗前比较,差异有统计学意义,p<0.01;治疗组治疗后与对照组治疗后,差异有统计学意义,p<0.05。②肺功能:各组治疗后与治疗前比较,差异有统计学意义,p<0.01;治疗组治疗后与对照组治疗后,差异有统计学意义,p<0.05。结论舒利迭吸入治疗慢性阻塞性肺病稳定期患者临床疗效显著,优于布地奈德吸入治疗,值得临床借鉴。
Objective To investigate the clinical efficacy of seretide in the treatment of chronic obstructive pulmonary disease (COPD) at stable phase. Methods 112 cases of chronic obstructive pulmonary disease in our hospital from February 2007 to February 2009 were selected, all of whom were stable patients. The above patients were randomly divided into control group and treatment group. Control group, 54 cases of inhaled budesonide 0.3mg, 2 times / d on the basis of routine treatment. In the treatment group, 58 patients were ingested by inhalation of seretide (salmeterol 50 μg and fluticasone propionate 250 μg) on the basis of routine treatment, and once or twice a day for 12 hours. The two groups of treatment a total of 8W. Before treatment and after the end of treatment, the lung function of the two groups was tested and their clinical symptoms were scored. Results After the end of the course of treatment, ① clinical symptom score: each group after treatment compared with before treatment, the difference was statistically significant, p <0.01; treatment group and control group after treatment, the difference was statistically significant, p <0.05. (2) Pulmonary function: The difference between the two groups after treatment was statistically significant (p <0.01). After treatment, the difference between the two groups was statistically significant (p <0.05). Conclusion Seretide inhalation in patients with stable chronic obstructive pulmonary disease clinical efficacy was significantly better than budesonide inhalation, it is worth learning from.